Evidence map›Paper›PMID 38717637›Full record

ArticleMolecular biology reports2024

A new perspective on therapies involving B-cell depletion in autoimmune diseases.

Sulieman Ibraheem Shelash Al-Hawary, Saade Abdalkareem Jasim, Ahmed Hjazi, Himayat Ullah, Pooja Bansal, Mahamedha Deorari, I B Sapaev, Ahmed Ali Ami, Karrar Hatif Mohmmed, Munther Kadhim Abosaoda

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Sulieman Ibraheem Shelash Al-HawaryAl Al-Bayt University, Al-Mafraq, Jordan.
Saade Abdalkareem JasimMedical Laboratory Techniques Department, Al-Maarif University College, Anbar, Iraq.
Ahmed HjaziDepartment of Medical Laboratory, College of Applied Medical Sciences, Prince Sattam Bin Abdulaziz University, 11942, Al-Kharj, Saudi Arabia.
Himayat UllahCollege of Medicine, Shaqra University, 15526, Shaqra, Saudi Arabia. Himayatullah@su.edu.sa.
Pooja BansalDepartment of Biotechnology and Genetics, Jain (Deemed-to-Be) University, Bengaluru, Karnataka, 560069, India.
Mahamedha DeorariUttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, India.
I B SapaevTashkent Institute of Irrigation and Agricultural Mechanization Engineers National Research University, Tashkent, Uzbekistan.
Ahmed Ali AmiDepartment of Medical Laboratories Technology, Al-Nisour University College, Baghdad, Iraq.
Karrar Hatif MohmmedScientific Research Center, Al-Ayen University, Thi-Qar, 64001, Iraq.
Munther Kadhim AbosaodaCollege of Pharmacy, The Islamic University, Najaf, Iraq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It has been rediscovered in the last fifteen years that B-cells play an active role in autoimmune etiology rather than just being spectators. The clinical success of B-cell depletion therapies (BCDTs) has contributed to this. BCDTs, including those that target CD20, CD19, and BAFF, were first developed to eradicate malignant B-cells. These days, they treat autoimmune conditions like multiple sclerosis and systemic lupus erythematosus. Particular surprises have resulted from the use of BCDTs in autoimmune diseases. For example, even in cases where BCDT is used to treat the condition, its effects on antibody-secreting plasma cells and antibody levels are restricted, even though these cells are regarded to play a detrimental pathogenic role in autoimmune diseases. In this Review, we provide an update on our knowledge of the biology of B-cells, examine the outcomes of clinical studies employing BCDT for autoimmune reasons, talk about potential explanations for the drug's mode of action, and make predictions about future approaches to targeting B-cells other than depletion.

Indexed as

Autoimmune DiseasesB-LymphocytesLymphocyte DepletionAnimalsAntigens, CD19Antigens, CD20B-Cell Activating FactorHumansLupus Erythematosus, SystemicMultiple SclerosisAntigens, CD19Antigens, CD20B-Cell Activating FactorAutoimmune diseasesBCDTB-cellB-cell depletion therapies

Identifiers

PMID38717637

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.